
Sign up to save your podcasts
Or
Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.
Timestamps
1:16 - Panel introductions
References
Fidaxomicin Cost-effectiveness
Bezlotoxumab
Bezlotoxumab Cost-effectiveness
Primary prophylaxis
Secondary prophylaxis
4.9
149149 ratings
Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.
Timestamps
1:16 - Panel introductions
References
Fidaxomicin Cost-effectiveness
Bezlotoxumab
Bezlotoxumab Cost-effectiveness
Primary prophylaxis
Secondary prophylaxis
1,856 Listeners
478 Listeners
3,320 Listeners
1,084 Listeners
176 Listeners
512 Listeners
318 Listeners
245 Listeners
413 Listeners
244 Listeners
365 Listeners
172 Listeners
24 Listeners
80 Listeners
203 Listeners